Sep 23 2026 10:21 PM EST
Absci Shares Rise on $40 Million Lilly Investment and Positive Phase‑1 Data
September 23, 2026
Absci Corp (NASDAQ:ABSI) closed at $9.74 on September 23, 2026, up 34.9% over the past five days after the company disclosed a $40 million strategic equity investment from Eli Lilly and reported positive interim Phase‑1 data for its lead antibody ABS‑201.
Revenue for Q2 2026 was $318,000, 67.8% below the $931,670 consensus and 46.0% lower year‑over‑year, while GAAP loss per share widened to ‑$0.21 versus the ‑$0.20 estimate. Net loss expanded to $33.2 million, but cash, cash equivalents and marketable securities rose to $201.1 million, extending the operating runway into the second half of 2028.
Lilly investment expands cash runway
Absci completed a $100 million underwritten offering, netting $93.6 million. The financing included a $40 million strategic equity investment from Eli Lilly, whose SVP of Clinical Investigation joined Absci’s Endometriosis Advisory Board. No program rights were transferred. The proceeds lifted cash reserves to $201.1 million, providing sufficient liquidity to fund operations into the second half of 2028.
Phase‑1 data supports ABS‑201 development
Interim data from the HEADLINE Phase‑1 trial showed favorable safety, tolerability and an estimated half‑life of at least 65 days, supporting a dosing regimen of 2‑3 injections over six months to maintain >90% receptor occupancy. Management plans to initiate a Phase‑II endometriosis study for ABS‑201 in Q4 2026, with interim proof‑of‑concept readout expected in late 2026 and full 26‑week data projected for early 2027.
Analyst coverage and valuation outlook
Needham reiterated a Buy rating with a price target of $11.00 (09/23/2026). BTIG raised its target to $16.00, and HC Wainwright lifted its target to $16.00. Truist increased its target to $17.00. The consensus 12‑month target sits around $13.8, with a range of $10‑$17. Short interest stands at 35.09 million shares (≈28.1% of float), representing about 15.2 days to cover and up 12.9% since September 2025. Insiders have bought roughly $149 K of stock in the past 90 days.
AI‑driven discovery and sector tailwinds
Absci’s Atlas discovery engine delivers a 1,000‑fold reduction in library size, which the company says can cut discovery costs by up to 75% and accelerate timelines by roughly 14 months. The broader biotech sector has benefited from renewed investor interest in AI‑enabled drug discovery, and the FDA released a discussion paper on regulating generative‑AI medical devices on 08/18/2026, signaling a maturing regulatory environment. Biotech ETFs have posted gains, reflecting a stabilising macro‑environment and moderate interest‑rate outlook.
Risks and unanswered questions
Absci remains a pre‑revenue company; Q2 2026 revenue of $0.32 million fell well short of expectations. The business continues to incur sizable losses, with a net loss of $33.2 million for the quarter. Success hinges on the ability of ABS‑201 to achieve proof‑of‑concept in both hair‑loss and endometriosis indications. Regulatory uncertainty remains, as no AI‑designed drug has yet received FDA approval. High short interest and the concentration of the share float could amplify price volatility on future news.